Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scinai Immunotherapeutics Ltd ADR (NQ: SCNI )

3.680 +0.270 (+7.92%)
Streaming Delayed Price Updated: 1:35 PM EDT, Sep 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,499
Open 3.480
Bid (Size) 3.620 (2)
Ask (Size) 3.700 (1)
Prev. Close 3.410
Today's Range 3.480 - 3.738
52wk Range 2.230 - 9.430
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Schedules Virtual Panel Discussion on Plaque Psoriasis, Its Promising Novel Solution
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast
Via Investor Brand Network

Performance

YTD
-39.64%
-39.64%
1 Month
-11.75%
-11.75%
3 Month
+9.52%
+9.52%
6 Month
-27.84%
-27.84%
1 Year
-59.16%
-59.16%

More News

Read More
New Approach Could Boost Effectiveness of Immunotherapies Against Colorectal Cancer
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), EIB Close on Loan Restructuring Agreement
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder
Via Investor Brand Network
SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024
Via InvestorPlace
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q2 2024 Financial Results, Shares Business Update
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Signs Definitive Loan Restructuring Agreement with EIB Converting Debt into Equity
Via Investor Brand Network
Australia Launches Novel Immunotherapy Program to Help Babies with Peanut Allergies
Via Investor Brand Network
7 F-Rated Stocks for Your August 2024 Sell List
Via InvestorPlace
Study Highlights Heightened Risk of Diseases Spreading from Animals to Humans
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives PEI Feedback Regarding Development, Preclinical Trial of Anti-IL-17 NanoAb
Via Investor Brand Network
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results
Via Benzinga
Exposures Fossil Fuels
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
PLUG Stock Alert: Plug Power Gets Approval for HyVia Acquisition
Via InvestorPlace
M Stock Plunges 13% as Macy’s Calls Off Take-Private Talks
Via InvestorPlace
Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
Via Benzinga
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?
Via InvestorPlace
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study
Via Investor Brand Network
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July
Via Benzinga
Topics Stocks
Exposures US Equities
Study Explores Starving Malignant Cells to Boost Immunotherapy, Improve DNA Damage
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Updated LoI from the European Investment Bank
Via Investor Brand Network
SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q1 2024
Via InvestorPlace
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q1 2024 Financial Reports, Business Update
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.